• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    ReWalk Robotics And 3 Other Stocks Under $2 Insiders Are Buying

    9/7/23 9:05:34 AM ET
    $CVKD
    $ORGN
    $RWLK
    $VNRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Major Chemicals
    Industrials
    Get the next $CVKD alert in real time by email

    The Dow Jones closed lower by around 200 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

    Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.

    VolitionRx

    • The Trade: VolitionRx Limited (NYSE:VNRX) Director Phillip Barnes acquired a total of 5,000 shares an average price of $1.30. To acquire these shares, it cost around $6,500.
    • What’s Happening: VolitionRX posted a narrower-than-expected quarterly loss.
    • What VolitionRx Does: VolitionRX Ltd is a United states based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost effective blood tests to help diagnose and monitor a range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19.

    Cadrenal Therapeutics

    • The Trade: Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) Chairman and CEO Quang Pham acquired a total of 40,000 shares at an average price of $0.90. The insider spent around $36,188.
    • What’s Happening: Cadrenal Therapeutics highlighted additional need for a new vitamin k antagonist following updates from the recent European Society of Cardiology Congress.
    • What Cadrenal Therapeutics Does: Cadrenal Therapeutics Inc is focused on developing a novel therapy with orphan drug indication, tecarfarin, for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease (on dialysis) and atrial fibrillation (irregular heartbeat) or AFib.

    Origin Materials

    • The Trade: Origin Materials, Inc. (NASDAQ:ORGN) Director R. Tony Tripeny acquired a total of 73,000 shares at an average price of $1.37. To acquire these shares, it cost around $100,054.
    • What’s Happening: Origin Materials announced appointment of Pam Haley as interim Chief Financial Officer.
    • What Origin Materials Does: Origin Materials Inc is a carbon-negative materials company. The platform turns the carbon found in biomass into useful materials, while eliminating the need for fossil resources and capturing carbon in the process.

    Check This Out: Top 5 Health Care Stocks That May Explode In Q3

    Don’t forget to check out our premarket coverage here

    ReWalk Robotics

    • The Trade: ReWalk Robotics Ltd. (NASDAQ:RWLK) 10% owner Lind Global Fund II LP acquired a total of 31,537 shares at an average price of $0.70. The insider spent $22,190 to buy those shares.
    • What’s Happening: ReWalk Robotics posted downbeat results for the second quarter.
    • What ReWalk Robotics Does: ReWalk Robotics Ltd is an Israel based medical device company. It is engaged in designing, developing and commercializing the Rewalk systems which are exoskeletons allowing wheelchair-bound individuals to stand and walk once again.
    Get the next $CVKD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CVKD
    $ORGN
    $RWLK
    $VNRX

    CompanyDatePrice TargetRatingAnalyst
    VolitionRX Limited
    $VNRX
    4/8/2025$2.50Buy
    H.C. Wainwright
    Origin Materials Inc.
    $ORGN
    1/14/2025$2.50 → $1.50Buy → Underperform
    BofA Securities
    Origin Materials Inc.
    $ORGN
    8/16/2024$1.35 → $3.00Neutral → Buy
    BofA Securities
    Cadrenal Therapeutics Inc.
    $CVKD
    12/18/2023$4.00Outperform
    Noble Capital Markets
    Origin Materials Inc.
    $ORGN
    8/11/2023$2.00Buy → Hold
    Craig Hallum
    VolitionRX Limited
    $VNRX
    2/1/2023Buy → Hold
    The Benchmark Company
    Origin Materials Inc.
    $ORGN
    10/14/2022$7.00Outperform
    Credit Suisse
    Origin Materials Inc.
    $ORGN
    3/1/2022$10.00 → $7.00Neutral
    Goldman Sachs
    More analyst ratings

    $CVKD
    $ORGN
    $RWLK
    $VNRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Commercial Officer Forterre Gael covered exercise/tax liability with 2,010 shares, decreasing direct ownership by 1% to 189,872 units (SEC Form 4)

    4 - VOLITIONRX LTD (0000093314) (Issuer)

    2/3/26 4:05:22 PM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Secretary Rootsaert Rodney Gerard covered exercise/tax liability with 3,196 shares, decreasing direct ownership by 2% to 162,262 units (SEC Form 4)

    4 - VOLITIONRX LTD (0000093314) (Issuer)

    2/3/26 4:05:11 PM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    GC - Volition Diagnostics Plummer Nicholas covered exercise/tax liability with 5,647 shares, decreasing direct ownership by 2% to 233,137 units (SEC Form 4)

    4 - VOLITIONRX LTD (0000093314) (Issuer)

    2/3/26 4:05:05 PM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $CVKD
    $ORGN
    $RWLK
    $VNRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Origin Materials Announces Organizational Realignment and Business Update

    — PET pressurized water caps slated for delivery to multiple marquee global beverage brands in Q1 2026 to continue their acceptance testing — — The Company is enhancing its cash resources through non-dilutive measures — — Reaffirms Adjusted EBITDA run-rate breakeven in 2027, revises revenue guidance — Origin Materials ("Origin") (NASDAQ:ORGN, ORGNW)), a technology company with a mission to enable the world's transition to sustainable materials, today announced an organizational realignment and cost containment measures reflecting proactive steps to enhance its cash and capital resources dedicated to PET cap commercialization to allow Origin to achieve Adjusted EBITDA run-rate breakeve

    2/12/26 7:00:00 AM ET
    $ORGN
    Major Chemicals
    Industrials

    Volition Announces the Appointment of New Distributor for Nu.Q® Discover

    HENDERSON, Nev., Feb. 10, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, announces the appointment of Medical & Biological Laboratories Co. Ltd (MBL) as a non-exclusive distributor of its Nu.Q® Discover assays in Japan. Dr Jasmine Kway, Chief Executive Officer, Singapore Volition commented: "We are delighted to be working with MBL, a leading provider of clinical research tools in Japan, with a particular focus and track record in autoimmune diseases. "Through our Nu.Q® Discover pillar, we are now serving close to 100 clients worldwide, including many top pharma and diagnostic companies, accelerating disease research and drug developme

    2/10/26 8:07:00 AM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    VolitionRx Receives Notice of Non-Compliance with NYSE American Continued Listing Standards

    HENDERSON, Nev., Feb. 9, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, announced today that on February 6, 2026, it received a notice (the "Notice") from the NYSE American LLC (the "NYSE American") stating that the Company is not in compliance with the NYSE American continued listing standards set forth in Section 1003(a)(i) of the NYSE American Company Guide (the "Company Guide") requiring a company to have stockholders' equity of at least $2.0 million if it has reported losses from continuing operations and/or net losses in two of its three most recent fiscal years, Section 1003(a)(ii) of the Company Guide requiring

    2/9/26 5:20:00 PM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $CVKD
    $ORGN
    $RWLK
    $VNRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on VolitionRx with a new price target

    H.C. Wainwright initiated coverage of VolitionRx with a rating of Buy and set a new price target of $2.50

    4/8/25 8:02:28 AM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Origin Materials downgraded by BofA Securities with a new price target

    BofA Securities downgraded Origin Materials from Buy to Underperform and set a new price target of $1.50 from $2.50 previously

    1/14/25 8:05:44 AM ET
    $ORGN
    Major Chemicals
    Industrials

    Origin Materials upgraded by BofA Securities with a new price target

    BofA Securities upgraded Origin Materials from Neutral to Buy and set a new price target of $3.00 from $1.35 previously

    8/16/24 7:44:03 AM ET
    $ORGN
    Major Chemicals
    Industrials

    $CVKD
    $ORGN
    $RWLK
    $VNRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Reynolds Cameron John bought $7,000 worth of shares (20,000 units at $0.35), increasing direct ownership by 0.79% to 2,554,847 units (SEC Form 4)

    4 - VOLITIONRX LTD (0000093314) (Issuer)

    11/17/25 1:12:19 PM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    President and CEO Reynolds Cameron John bought $56,100 worth of shares (110,000 units at $0.51), increasing direct ownership by 5% to 2,534,847 units (SEC Form 4)

    4 - VOLITIONRX LTD (0000093314) (Issuer)

    10/15/25 4:05:45 PM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Director Innes Guy Archibald bought $49,038 worth of shares (96,153 units at $0.51), increasing direct ownership by 10% to 1,062,967 units (SEC Form 4)

    4 - VOLITIONRX LTD (0000093314) (Issuer)

    10/15/25 4:05:33 PM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $CVKD
    $ORGN
    $RWLK
    $VNRX
    SEC Filings

    View All

    VolitionRX Limited filed SEC Form 8-K: Unregistered Sales of Equity Securities, Financial Statements and Exhibits

    8-K - VOLITIONRX LTD (0000093314) (Filer)

    2/20/26 5:15:32 PM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form EFFECT filed by VolitionRX Limited

    EFFECT - VOLITIONRX LTD (0000093314) (Filer)

    2/20/26 12:15:15 AM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Origin Materials Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - Origin Materials, Inc. (0001802457) (Filer)

    2/18/26 4:05:54 PM ET
    $ORGN
    Major Chemicals
    Industrials

    $CVKD
    $ORGN
    $RWLK
    $VNRX
    Leadership Updates

    Live Leadership Updates

    View All

    Volition Announces the Appointment of New Distributor for Nu.Q® Discover

    HENDERSON, Nev., Feb. 10, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, announces the appointment of Medical & Biological Laboratories Co. Ltd (MBL) as a non-exclusive distributor of its Nu.Q® Discover assays in Japan. Dr Jasmine Kway, Chief Executive Officer, Singapore Volition commented: "We are delighted to be working with MBL, a leading provider of clinical research tools in Japan, with a particular focus and track record in autoimmune diseases. "Through our Nu.Q® Discover pillar, we are now serving close to 100 clients worldwide, including many top pharma and diagnostic companies, accelerating disease research and drug developme

    2/10/26 8:07:00 AM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Volition Continues to Extend Access to Nu.Q® Vet Cancer Test

    HENDERSON, Nev., Jan. 20, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, announces the appointment of two new centralized laboratory providers of its Nu.Q® Vet Cancer test in the U.S. and Asia, further expanding access to its canine cancer early detection tool. Midwest Veterinary Laboratory, a full-service independent reference laboratory in the U.S., will be offering the Nu.Q® Vet Cancer test to its customers across all 50 states from February 2026.Bioguard, a global animal health diagnostics company is now offering the Nu.Q® Vet Cancer Test through it's Animal Health Diagnostic Center, the first certified ISO/IEC 17025 animal diseas

    1/20/26 8:25:00 AM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Cadrenal Therapeutics Appoints Dr. Lee Golden to Board of Directors

    PONTE VEDRA, Fla., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a biopharmaceutical company developing transformative therapeutics to overcome current gaps in anticoagulation therapy, today announced the appointment of Lee Scott Golden, M.D., to its Board of Directors, effective immediately. Dr. Golden will serve as an independent director. Dr. Golden currently serves as Executive Vice President and Chief Medical Officer at PTC Therapeutics, Inc. (NASDAQ:PTCT), where he leads global clinical development across a broad rare disease pipeline. Before joining PTC, Dr. Golden served as the Chief Medical Officer at Espero BioPharma, Inc., a development-stage card

    12/1/25 9:00:00 AM ET
    $CVKD
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CVKD
    $ORGN
    $RWLK
    $VNRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by VolitionRX Limited

    SC 13G - VOLITIONRX LTD (0000093314) (Subject)

    11/14/24 4:05:14 PM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Amendment: SEC Form SC 13G/A filed by Cadrenal Therapeutics Inc.

    SC 13G/A - Cadrenal Therapeutics, Inc. (0001937993) (Subject)

    11/14/24 4:00:17 PM ET
    $CVKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by VolitionRX Limited

    SC 13G - VOLITIONRX LTD (0000093314) (Subject)

    11/14/24 3:40:04 PM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $CVKD
    $ORGN
    $RWLK
    $VNRX
    Financials

    Live finance-specific insights

    View All

    Cadrenal Therapeutics Acquires VLX-1005, a First-in-Class Phase 2 12-LOX Inhibitor for Patients with Heparin-Induced Thrombocytopenia (HIT)

    Novel first-in-class therapeutic targeting a key immune signaling pathway and the underlying cause of HITIt is the first and only potent, highly selective inhibitor of human 12-LOX in clinical testing, distinguishing it from related compounds.Orphan Drug and Fast Track designations from the FDA PONTE VEDRA, Fla., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a biopharmaceutical company developing transformative therapeutics to overcome the limitations of current anticoagulation therapy, today announced the acquisition of VLX-1005 and related 12-lipoxygenase (12-LOX) assets from Veralox Therapeutics ("Veralox"). The acquisition immediately strengthens Cadren

    12/11/25 8:05:00 AM ET
    $CVKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cadrenal Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

    PONTE VEDRA, Fla., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a biopharmaceutical company developing transformative therapeutics to overcome current gaps in anticoagulation therapy, today reported its financial results for the third quarter ended September 30, 2025, and provided an update on the clinical development of tecarfarin and the acquisition and development of frunexian. Highlights Progressed clinical development of tecarfarin. Completed the manufacturing of tecarfarin drug product in accordance with current good manufacturing practices (cGMP).Ongoing activities in support of a single-site U.S. Phase 2 study of tecarfarin in LVAD patients as part

    11/10/25 9:00:00 AM ET
    $CVKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    VolitionRx Limited Schedules Third Quarter 2025 Earnings Conference Call and Business Update

    Conference call to take place on Friday, November 14 at 8:30 a.m. U.S. Eastern Time HENDERSON, Nev., Nov. 10, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition") today announces that it will host a conference call on Friday, November 14 at 8.30 a.m. U.S. Eastern Time to discuss its financial and operating results for the third quarter of 2025 and to provide a business update. Details of this event can be found below. Event:   VolitionRx Limited Third Quarter 2025 Earnings and Business Update Conference Call Date:     Friday, November 14, 2025Time:    8:30 a.m. U.S. Eastern Time/2.30 p.m. Central European Time U.S. & Canada Dial-in: 1-877-407-9716 (toll free)U.K. Dial-in: 0 800

    11/10/25 8:45:00 AM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care